Navigation Links
Psychemedics Corporation Announces Third Quarter Results

$0.17 Dividend Declared

ACTON, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Psychemedics Corporation (Nasdaq: PMD) today announced third quarter financial results for the period ended September 30, 2008. The Company also announced a quarterly dividend of $0.17 per share payable to shareholders of record as of December 3, 2008 to be paid on December 17, 2008. This will be the Company's 49th consecutive quarterly dividend.

The Company's third quarter revenue was $6.2 million, down 4% as compared to $6.5 million in the third quarter of 2007. Net income was $0.9 million or $0.17 per diluted share, down 28% from $1.2 million or $0.23 per share for the same period in 2007. The Company's revenue for the nine months ended September 30, 2008 was $18.1 million, down 3% as compared to $18.7 million for the comparable period of 2007. Net income for the nine months ended September 30, 2008 was $2.8 million or $0.53 per diluted share, a decrease of 22% over the comparable period last year during which the Company earned $3.6 million or $0.67 per diluted share.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said, "We are operating in a tough hiring environment. However, we continued to add new accounts at a healthy pace which has served as a significant offset to the general weakness in hiring."

Kubacki continued, "We are continuing to make investments in our sales and marketing group to capitalize on significant future growth opportunities. We believe this will continue to pay off with a steady stream of new customer wins. While these are uncertain times, our services save customers a significant cost, which is why we remain confident in our future."

Kubacki concluded, "We remain a solidly profitable company with a promising outlook. It is important to also note that the Company continues to have a strong balance sheet with no long-term debt and approximately $9.1 million of cash and investments, up 9% from the third quarter of 2007. Therefore, we are declaring our 49th consecutive quarterly dividend. This dividend demonstrates our continued commitment to maximizing shareholder returns as we move forward."

On March 17, 2008, the Company announced the authorization of a 250,000 share stock repurchase program and the Company continued to buy back its own shares in the third quarter.

Psychemedics is the world's largest provider of hair testing for drugs of abuse with thousands of corporations relying on the patented Psychemedics drug testing services. Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America and six Federal Reserve Banks.

Financial Summary:

-- Revenue for the third quarter of $6.2 million, down 4% from the prior year quarter

-- Revenue for the nine month period of $18.1 million, down 3% from the prior year period

-- Pretax income for the third quarter of $1.4 million, down 29% from the prior year quarter

-- Pretax income for the nine month period of $4.7 million, down 22% from the prior year period

-- Net income for the third quarter of $0.9 million, or $0.17 per diluted share, down 27% from the prior year quarter

-- Net income for the nine month period of $2.8 million, or $0.53 per diluted share, down 21% from the prior year period

The Psychemedics web site is

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, growth opportunities, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward looking" statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing team, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.






2008 2007 2008 2007

REVENUE $6,204,647 $6,463,516 $18,124,587 $18,677,412

DIRECT COSTS $2,552,014 2,553,358 7,374,228 7,395,552

Gross profit 3,652,633 3,910,158 10,750,359 11,281,860


General and

administrative 1,145,486 1,108,625 3,262,804 2,969,680

Marketing and

selling 1,013,510 765,145 2,714,882 2,277,075

Research and

development 125,039 121,859 362,532 377,481

2,284,035 1,995,629 6,340,218 5,624,236

OPERATING INCOME 1,368,598 1,914,529 4,410,141 5,657,624

INTEREST INCOME 64,999 104,480 249,961 302,048


INCOME TAXES 1,433,597 2,019,009 4,660,102 5,959,672


TAXES 560,042 809,400 1,864,041 2,382,800

NET INCOME $873,555 $1,209,609 $2,796,061 $3,576,872


SHARE $0.17 $0.23 $0.54 $0.69


SHARE $0.17 $0.23 $0.53 $0.67



OUTSTANDING, BASIC 5,226,237 5,216,386 5,223,581 5,199,876



OUTSTANDING, DILUTED 5,255,301 5,333,341 5,275,311 5,301,756




September December

30, 2008 31, 2007




Cash and cash equivalents $6,910,753 $6,096,734

Short-term investments 2,150,000 3,875,000

Accounts receivable, net of

allowance for doubtful

accounts of $235,891 in 2008 and

$235,337 in 2007 4,312,292 3,555,342

Prepaid expenses and other current

assets 840,290 498,919

Deferred tax asset 531,930 429,472

Total current assets 14,745,265 14,455,467


Less-accumulated depreciation and

amortization (10,225,849) (9,977,315)

654,021 815,342

DEFERRED TAX ASSET 231,346 231,346

OTHER ASSETS - NET 74,375 58,613

$15,705,007 $15,560,768



Accounts payable $434,213 $488,640

Accrued expenses 1,166,457 951,242

Deferred revenue 166,261 242,955

Total current liabilities 1,766,931 1,682,837


Preferred stock, $.005 par value;

authorized 872,521 shares; none


Common stock; $.005 par value;

authorized 50,000,000 shares;

5,843,068 shares issued in

2008 and 5,811,982 shares issued

in 2007 29,215 29,060

Paid-in capital 27,003,835 26,539,764

Accumulated deficit (3,293,751) (3,527,269)

Less - Treasury stock, at cost;

626,848 shares in 2008 and 586,197

shares in 2007 (9,801,223) (9,163,624)

Total shareholders' equity 13,938,076 13,877,931

$15,705,007 $15,560,768

Contact: Raymond Ruddy

Vice President and Controller

(978) 206-8220

SOURCE Psychemedics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Raymond J. Ruddy Joins Psychemedics Corporation As Top Financial Officer
2. Psychemedics Corporation Announces Second Quarter Results
3. Psychemedics Corporation Announces First Quarter Results
4. Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue
5. Jennifer Chmieleski Joins Psychemedics Corporation as Top Financial Officer
6. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
7. Somanetics Corporation to Present at Rodman & Renshaw Annual Global Investment Conference
8. STERIS Corporation Announces Webcast of Analyst Conference
9. Hemingway Hall Named CEO of Health Care Service Corporation
10. Chem Rx Corporation Schedules 2008 Annual Meeting Date
11. Torchmark Corporation Declares Dividend
Post Your Comments:
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is a ... filling out a survey; in many cases health professionals and patients are working together ... research on the importance of active engagement with patients and members of the public ...
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology: